Guy Charles Fanneau de la Horie
Independent Board member including Angels Santé and Genflow Biosciences
Over the past 20 years, Guy-Charles has built, and led, biotech executive teams where he has acted as Chief Executive Officer. During his tenures, he has successfully led IPOs and completed multiple fundraisings. Guy-Charles’ expertise in the biotech field in both public and private companies encompasses launching and selling new drugs in untapped markets, with successful early access programs.
Specifically, Guy-Charles has served as Chief Executive Officer at three biotech companies, including, until very recently, Euronext Growth traded, Pherecydes Pharma, a biotech company that develops treatments against resistant bacterial infections; and Neovacs, a therapeutic vaccine company. Guy-Charles has also held senior positions at Biogen, a Nasdaq listed global biotechnology company. Guy-Charles managed the IPO and associated successful financing of Neovacs in 2010, and in 2021, led Pherecydes Pharma through an oversubscribed placing.
Visit website: https://genflowbio.com/leadership/#guy
guy-charles-fanneau-de-la-horie-9294597
See also: Genflow Biosciences - Developing medicines that potentially halt, slow or reverse the aging process
Details last updated 20-Aug-2022